Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography
NCT ID: NCT03122769
Last Updated: 2018-04-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
6 participants
INTERVENTIONAL
2017-12-01
2018-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to investigate if metformin is taken up in heart failure using a novel 11C-metformin tracer and positron emission tomography (PET).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Metformin Treatment on Myocardial Efficiency in Patients With Heart Failure
NCT02810132
Management of Diabetes With Metformin In Patients With Chronic Heart Failure
NCT01122316
A Pilot Study: Metformin Therapy in Heart Failure Patients With Early Diabetes or at High Risk of Developing Diabetes (Pre-Diabetes)
NCT01573949
Effects of Experimental Hyperketonemia on Myocardial Metabolism
NCT02814474
Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment
NCT04177303
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
11C-metformin
All participants allocated to the study will be included in this arm
11C-metformin
200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
11C-metformin
200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* New York Heart Association (NYHA) class I, II, III
* Relatively preserved renal function (eGFR \> 30 ml/min)
* Ability to understand the written patient information and to give informed consent
* Negative p-HCG for women of childbearing potential
Exclusion Criteria
* Age \< 18 years
* Current abuse of alcohol or drugs
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henrik Wiggers
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Henrik Wiggers
Senior consultant, associate professor, MD, PhD, DMSc
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital, Department of Cardiology, Palle Juul-Jensens Boulevard 99
Aarhus N, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-003453-15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.